Humacyte (HUMA) Non-Current Debt (2020 - 2026)
Humacyte (HUMA) posted quarterly Non-Current Debt of $35.9 million for Q1 2026, down 45.95% year-over-year from $66.4 million in Q1 2025, and up 1.2% quarter-over-quarter from $35.4 million in Q4 2025.
Humacyte (HUMA) Non-Current Debt (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Non-Current Debt for 7 consecutive years, with $35.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt fell 45.95% year-over-year to $35.9 million; the TTM figure through Mar 2026 stood at $35.9 million (down 45.95% YoY), while the FY2025 annual figure was $35.4 million, changed N/A from the prior year.
- Non-Current Debt advanced to $35.9 million in Q1 2026 per HUMA's latest filing, from $35.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $68.5 million in Q2 2025 and bottomed at $17.7 million in Q3 2025.
- Historically, Non-Current Debt has averaged $41.2 million across 5 years, with a median of $36.2 million in 2023.
- Annual changes were most pronounced in 2023 — Non-Current Debt surged 89.81% — and 2025, when it sank 71.55%.
- Humacyte's Non-Current Debt stood at $20.3 million in 2022, then soared by 89.81% to $38.6 million in 2023, then jumped by 60.92% to $62.1 million in 2024, then tumbled by 42.94% to $35.4 million in 2025, then advanced by 1.2% to $35.9 million in 2026.
- Business Quant data shows HUMA's Non-Current Debt at $35.9 million in Q1 2026, $35.4 million in Q4 2025, and $17.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 36.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.32 Mn |
| Mar 31, 2026 | 35.87 Mn |
| Dec 31, 2025 | 35.44 Mn |
| Sep 30, 2025 | 17.67 Mn |
| Jun 30, 2025 | 68.54 Mn |
| Mar 31, 2025 | 66.36 Mn |
| Sep 30, 2024 | 62.12 Mn |
| Jun 30, 2024 | 60.08 Mn |
| Mar 31, 2024 | 57.96 Mn |
| Dec 31, 2023 | 38.60 Mn |
| Sep 30, 2023 | 37.29 Mn |
| Jun 30, 2023 | 36.25 Mn |
| Dec 31, 2022 | 20.34 Mn |
| Sep 30, 2022 | 24.29 Mn |
| Jun 30, 2022 | 30.00 Mn |
| Mar 31, 2022 | 27.74 Mn |
| Dec 31, 2021 | 27.36 Mn |
| Sep 30, 2021 | 14.04 Mn |
| Dec 31, 2020 | 822,000.00 |